International Symposium on HAI:
Antimicrobial stewardship, a multidisciplinary approach

Hotel Tequendama, Bogota D. C
February 26-27, 2015

Registration: USD 175
THURSDAY FEB 26

ROLE OF THE MICROBIOLOGY LAB
Conveners: Adriana Correa and German Esparza

8:30-9:00 Welcome

9:00 – 9:30 Incorporating the new CLSI breakpoints: limitations and benefits
Brandi Limbago

9:30 – 10:00 Can we incorporate PK/PD mechanisms of resistance and MIC in the Interpretation of the Antibiogram?
David Nicolau

10:00 – 10:30 Coffee break

10:30- 11:00 Confirmation and characterization of mechanisms of resistance: can we do it better?
Brandi Limbago

11:00 – 11:30 New methodologies for the ID of bacteria and fungus and its impact on an AMS program (Malditof, NP carb test, RT-PCR, PNA fish)
Adriana Correa

11:30- 12:00 Round table
THURSDAY FEB 26

THE ROLE OF THE PHARMACIST
Conveners: Ubier Gomez and Carlos Alvarez

2:00 – 2:30  The role of the pharmacy in an AMS program.
Debbie Goff

2:30 – 3:00  Incorporating PK/PD concepts for antibiotic therapy in children: where do we stand?
Ubier Gomez

3:00 – 3:30  How to pick the low hanging fruit in AMS
Debbie Goff

3:30 – 4:00  Coffee break

4:00 – 4:30  To buy or not to buy: generics against innovators on an AMS program
Cristhian Pallares

4:30 – 5:00  Round Table

5:00- 6:00  Clinical cases: Selecting the right antimicrobial therapy for the right patient
All speakers
### FRIDAY FEB 27

#### THE ROLE OF THE INFECTIOUS DISEASE

**Conveners:** Maria Virginia Villegas and Juan Diego Velez

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 8:30 – 9:00   | AMS programs: clinical, epidemiological and economic impact  
                | David Nicolau                                                                               |
| 9:00 – 9:30   | Make appropriate antimicrobial formulary decisions, and prepare optimal clinical pathways at  
                | a given institution  
                | Maria Virginia Villegas                                                                     |
| 9:30 – 10:00  | AMS in Gram (+) bacteria and its impact in the clinical decisions  
                | Esteban Nannini                                                                             |
| 10:00 – 10:30 | Coffee break                                                                               |
| 10:30 – 11:00 | The role of combination therapy and de-escalation for Gram (+) bacteria  
                | Esteban Nannini                                                                             |
| 11:00 – 11:30 | The importance of a Fungal Antimicrobial Stewardship (FAMS) in the ICU  
                | Juan Diego Velez                                                                             |
| 11:30 – 12:00 | Management of MDR bacteria: can we do better?  
                | Joseph Kuti                                                                                  |
FRIDAY FEB 27

THE ROLE OF THE EPIDEMIOLOGIST
Conveners: Christian Pallares and Stella Vanegas

2:00 – 2:30 Cleaning the environment: one size doesn’t fit all
William Rutala

2:30 – 3:00 Hospital outbreak investigations
Arjun Srinivasan

3:00 – 3:30 Coffee break

3:30 – 4:00 Vaccinating the adult hospitalized patient: benefits and challenges
David Weber

4:00- 4:30 Basic infection control processes and their inter-relationship with the environment
William Rutala

4:30 – 5:00 Incorporating the “Get Smart” strategy in your hospitals
Arjun Srinivasan

5:00 – 5:30 Selective vs universal surveillance cultures and decolonization for MDR bacteria: an update
David Weber

5:30- 6:00 Closure
WEDNESDAY FEB 25

7:00 -9:00 pm
AMS at the bedside of the patient: clinical cases
David Nicolau and Debbie Goff
(Sponsored by: MSD)

THURSDAY FEB 26

7:00–8:30 MEET THE EXPERT:
✓ PNA – Fish a reality for the microlab.
   To be defined.
   (Sponsored by: AdvanDx)

12:00–2:00 SATELLITE SYMPOSIA :
✓ Diagnostic value and prognostic evaluation of Presepsin for sepsis in different clinical settings.
   To be defined
   (Sponsored by: Velez Lab)

✓ Collateral Benefit vs Collateral Damage.
   David Nicolau.
   (Sponsored by: MSD)

✓ What an ID committee needs to know when assessing cleaning products.
   William Rutala
   (Sponsored by: WEST)
International Symposium on HAI:
Antimicrobial stewardship, a multidisciplinary approach

FRIDAY FEB 27

7:00– 8:30
MEET THE EXPERT:

✓ Pneumococcal vaccination in the adult patient: missed opportunities.
   David Weber
   (Sponsored by Pfizer)

✓ AMS: From the pharmacy to the patient: can we do better.
   David Nicolau
   (Sponsored by: MSD)

12:00– 2:00
SATELLITE SYMPOSIA:

✓ Cleaning and disinfecting hospital areas: Understanding the different bacteria in different areas.
   William Rutala
   (Sponsored by West)

✓ Treatment for MDR bacteria: a strategic approach.
   Joseph Kuti and Esteban Naninni.
   (Sponsored by Pfizer)
**International Symposium on HAI: Antimicrobial stewardship, a multidisciplinary approach**

**Brandi Limbago, PhD** is Deputy Branch Chief at Centers for Disease Control and Prevention (CDC). She received her PhD in Microbiology Molecular Genetics from Emory University. She subsequently completed her postdoctoral training at Children’s Hospital and Regional Medical Center, Seattle. Furthermore, Dr. Limbago has a senior fellow in Clinical and Public Health Management from University of Washington. Her research interests include Molecular Biology, Microbiology, Infectious Diseases and Public Health.

**David P. Nicolau, PharmD, FCCP, FIDSA** is the Director of the Center for Anti-Infective Research and Development at Hartford Hospital in Hartford, Connecticut. After graduating from Northeastern University, he completed a residency in hospital pharmacy at Boston University Medical Center. After receiving his PharmD from the Medical University of South Carolina, Dr. Nicolau completed a residency in adult internal medicine at the university’s affiliated hospital and a fellowship in Infectious Diseases at Hartford Hospital.

David Nicolau’s research activities involve a wide range of preclinical drug development studies to assess the in vitro potency, in vivo efficacy and toxicity profiles of novel compounds. He has been a principal investigator for Phase I – IV studies, as well as Investigational New Drug applications. Dr Nicolau is also widely recognized for his efforts focusing on the development of antimicrobial utilization strategies to improve outcomes and reduce the cost of care in the infected patient. David Nicolau’s investigations are reported in over 550 publications, 400 abstracts and 1,300 local, national or international presentations.
Debra Goff, PharmD, FCCP, Specialty Practice Pharmacist Infectious Diseases from the Ohio State University Medical Center.

Dr Goff joined The Ohio State University Medical Center in 1989 as an Infectious Disease Specialist. She is the director of the Infectious Diseases Residency program and a member of the Antimicrobial Stewardship Program (ASP). She is an Associate Professor at the College of Pharmacy. Dr. Goff received her bachelor of pharmacy degree, Doctor of Pharmacy degree, and performed her Pharmacy residency at the University of Illinois at Chicago.

As part of ASP, she is actively involved in developing strategies to control the escalating rate of antimicrobial resistance. The team manages both community acquired and healthcare associated infections. Most recently, she developed a medical “app” called STAB-IT (Staph aureus bacteremia - is terrible) to help educate clinicians at OSUMC on the management of patients with Staph aureus bacteremia by using the iPad. Her research interest includes antimicrobial resistance, clinical outcomes research, antifungals and innovative ways to educate using technology. She is an active member of IDSA, ACCP, ASM, SIDP, and a board member of the National Foundation for Infectious Diseases.

Dr. Esteban C. Nannini works as Infectious Diseases Specialist in Sanatorio Britanico (Rosario, Argentina). He received his Infectious Diseases degree from the Universidad Nacional de Rosario, (Argentina) and completed fellowships in Infectious Diseases and HIV/AIDS at the University of Texas Medical School at Houston.

Dr. Nannini has over 30 articles in peer-reviewed journals.

His research interests include infectious diseases caused by Gram positive bacteria, Immunology and Microbiology.
International Symposium on HAI: Antimicrobial stewardship, a multidisciplinary approach

Arjun Srinivasan, MD, MD (CAPT, USPHS), is associate director for healthcare-associated infection prevention programs in the Division of Healthcare Quality Promotion at CDC’s National Center for Emerging and Zoonotic Infectious Diseases. Dr. Srinivasan is also a captain in the US Public Health Service.

As infectious disease doctor, Dr. Srinivasan oversees several CDC programs aimed at eliminating healthcare-associated infections and improving antibiotic use. For much of his CDC career, Dr. Srinivasan ran the healthcare outbreak investigation unit, helping hospitals and other healthcare facilities track down bacteria and stop them from infecting other patients. Today, Dr. Srinivasan leads CDC’s work to improve antibiotic prescribing and works with a team of CDC experts researching new strategies to eliminate healthcare-associated infections.

Joseph L. Kuti, PharmD, is Associate Director of Clinical and Economic Studies at the Center for Anti-Infective Research and Development at Hartford Hospital in Hartford, Connecticut. He received his Bachelor of Science and Doctor of Pharmacy degrees from Rutgers University, College of Pharmacy in Piscataway, New Jersey. While completing his doctorate, he served as a clinical pharmacist for the medical and surgical intensive care units at Robert Wood Johnson University Hospital in New Brunswick, New Jersey.

He then completed a post-doctorate fellowship in Antibiotic Management and Pharmacoeconomics at Hartford Hospital. He is a member of the American Society for Microbiology, the American College of Clinical Pharmacy, and is currently Past-President for the Society of Infectious Diseases Pharmacists.

Dr Kuti’s primary area of research includes the pharmacokinetics, -dynamics, -economics, and outcomes of antimicrobial therapy in severe infections. His research has been published in many original research articles, book chapters, and reviews; furthermore, it has led to implementation of numerous clinical programs designed to optimize antibiotic use in hospitalized patients.
William Rutala, MS, MPH, PhD, is a Professor for the Division of Infectious Diseases at the University of North Carolina's School of Medicine, and serves as the Director of Hospital Epidemiology, Occupational Health and Safety Program at the University of North Carolina Health Care System. He is also Director and co-founder of the Statewide Program for Infection Control and Epidemiology at the UNC School of Medicine and a retired Colonel with the U.S. Army Reserve. Dr. Rutala is certified in infection control.

He is an advisor to the Centers for Disease Control and Prevention (a former member of the Healthcare Infection Control Practices Advisory Committee [HICPAC], 1999-2003), the Food and Drug Administration (a former member of the General Hospital and Personal Use Devices Panel), the U.S. Environmental Protection Agency (a member of the Scientific Advisory Panel on Antimicrobial Research Strategies for Disinfectants) and the Federal Trade Commission. Dr. Rutala is a member of various committees on the local, state, national and international level as well as several professional societies including the American Society for Microbiology, Association for Professionals in Infection Control and Epidemiology and the Society of Healthcare Epidemiology of America. He serves on the editorial board of the Infection Control and Hospital Epidemiology. He has 500 publications in the fields of infectious diseases, infection control, disinfection, sterilization and medical waste to include several guidelines (e.g., CDC Guideline for Disinfection and Sterilization in Healthcare Facilities). Dr. Rutala has also been an invited lecturer at over 300 state, national and international conferences (in over 40 states and 25 countries) and has testified twice before the U.S. Congress. Dr. Rutala earned his Bachelor of Science degree in science from Rutgers University, his master's degree in microbiology from the University of Tennessee and both his master's in public health and doctorate in microbiology from the University of North Carolina School of Public Health.
David Weber, M. D, MPH, received his Medical Degree (M.D.) from the University of California, San Diego, a Master’s in Public Health (M.P.H.) from Harvard University and completed his medicine residency and infectious disease fellowship at the Massachusetts General Hospital. He is Board Certified in Internal Medicine, Infectious Disease, Critical Care Medicine, and Preventive Medicine. Dr. Weber has been on the faculty of the University of North Carolina at Chapel Hill since 1985 where he is currently a Professor of Medicine and Pediatrics in the School of Medicine, and a Professor of Epidemiology in the School of Public Health.

Dr. Weber serves as the Associate Chief of Staff for UNC Health Care. He also serves as the Medical Director of the Departments of Hospital Epidemiology (Infection Control), Occupational Health, and Environmental Health and Safety for the UNC Health Care System. He is an Associate Director of the North Carolina Statewide Infection Control Program (SPICE) and serves as Director of the Regulatory Core for the UNC Clinical Translational Research Award. He chairs the NC State Health Department’s TB Advisory Committee. He is currently on two working groups of the ACIP.

Dr. Weber has published more than 160 scientific papers in the peer-reviewed literature. In addition he has published 4 monographs and more than 100 book chapters, editorials, and short papers. He serves as the Associate Editor for Infection Control and Hospital Epidemiology (ICHE). His research interests include the epidemiology of healthcare-associated infections, new and emerging infectious diseases, control of drug resistant pathogens, immunization practices (especially of healthcare workers), zoonotic diseases, and epidemiology of tuberculosis.